Combined protective effects of icariin and selenomethionine on novel chronic tubulointerstitial nephropathy models in vivo and in vitro. Issue 1 (14th January 2022)

• Record Type: Journal Article
• Authors: Hou, Lili; Lin, Ziman; Xu, Anyuan; Le, Guannan; Ge, Lei; Liu, Shuiping; Muhmood, Azhar; Gan, Fang; Huang, Kehe
• Is Part Of: British journal of nutrition. Volume 127:Issue 1(2022)
• Page Start: 12
• Page End: 22
• Publication Date: 2022-01-14
• Subjects: Icariin -- Selenomethionine -- Chronic tubulointerstitial nephropathy -- Renal fibrosis -- Toll-like receptor 4/NFκB signalling pathway; Nutrition -- Periodicals; 572.4
• DOI: 10.1017/S0007114521000787
• Languages: English
• ISSNs: 0007-1145

Abstract

Abstract: Chronic tubulointerstitial nephropathy (CTIN) is one of the most common kidney diseases. However, treatment for CTIN has multiple limits. Adjuvant therapy through nutritional regulation has become a hot research topic at present. Icariin (ICA), an extraction of Chinese herbal medicine epimedium, has many pharmacological functions including anti-inflammation and tonifying kidney. Selenomethionine (SeMet) possesses the effects of antioxidant and lightening nephrotoxicity. However, little is known about the combined nephroprotection of them. This study was investigated to evaluate the joint effects of ICA and SeMet on CTIN and explore the mechanism. Based on a novel CTIN model developed in our previous study, mice were randomly divided into five groups (a: control; b: model; c: model + ICA; d: model + SeMet; e: model + ICA + SeMet). Renal tubule epithelial cells were treated with cyclosporine A and ochratoxin A without/with ICA or/and SeMet. The results showed that ICA or/and SeMet ameliorated CTIN by inhibiting the uptrends of blood urine nitrogen, serum creatinine, urine protein, urine gravity, histopathological damage degree and collagen I deposition. ICA or/and SeMet also increased cell proliferation and decreased apoptosis and the expression of transforming growth factor-beta 1 and α -smooth muscle actin. Emphatically, ICA and SeMet joint had better nephroprotection than alone in most indexes including fibrosis. Furthermore, ICA and SeMet joint decreased the activation of toll-like receptor 4 (TLR4)/NFκB pathway induced by CTIN. TLR4 overexpression counteracted the joint protection of ICA and SeMet. Therefore, ICA and SeMet in combination could protect against CTIN through blocking TLR4/NFκB pathway. The study will provide novel insights to explore an adjuvant therapeutic orientation.